Clinical trial NCT04717700: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients
Official title: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe): An Investigator Sponsored Trial
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Multiple Myeloma
Keywords: selinexor
Lead sponsor: Odense University Hospital
Sponsor class: OTHER
Collaborators: name: Karyopharm Therapeutics Inc
name: Odense Patient Data Explorative Network
First posted: 2021-01-22
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: An unrandomized phase 2 study of selinexor in combination with lenalidomide/ bortezomib and dexamethasone to newly diagnosed, transplant in-eligible symptomatic multiple myeloma patients in a multicenter international set-up within the Nordic Multiple Myeloma Study Group

Detailed description: An unrandomized phase 2 study evaluating selinexor in combination with lenalidomide/ bortezomib and dexamethasone to newly diagnosed transplant in-eligible symptomatic multiple myeloma patients in a multicenter international set-up with in the Nordic Multiple Myeloma Study Group.

The study will include 50 patients, recruited within the NMSG collaborating countries. After induction patient will be treated with continued lenalidomide-dexamethasone according to SWOG, with continuous 40mg selinexor weekly in the selinexor arm (experimental arm B).

Eligibility criteria: Inclusion Criteria:

Inclusion Criteria:

Patients must meet all of the following inclusion criteria to be eligible to enroll in this study:

1. Age \> 18 years
2. Willing and able to provide written informed consent in accordance with national, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure
3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of ≤ 2. ECOG 3 allowed if caused by myeloma
4. Newly diagnosed multiple myeloma with treatment demanding disease as defined by IMWG (Rajkumar, Dimopoulos et al. 2014) and measurable disease as defined IMWG 2016 criteria (Table 5) (Kumar, Paiva et al. 2016)
5. By treating physician considered in-eligible for high-dose therapy with stem-cell transplant
6. Patients must have received no prior chemotherapy for multiple myeloma. Patients must have received no prior radiotherapy to a large area of the pelvis (more than half of the pelvis). Patients must have received no prior steroid treatment for myeloma with the exception of a maximum of 14 days of treatment for symptom control (including dexamethasone 40mg).
7. Adequate hepatic function within 7 days prior to C1D1:

   1. Total bilirubin \< 1.5 × upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of \< 3 × ULN), and
   2. Alanine aminotransferase (ALT) normal to \<2 × ULN.
8. Adequate renal function within 7 days prior to C1D1 as determined by estimated GFR of ≥ 30 mL/min, calculated using standard formula.

   1. Adequate hematopoietic function within 7 days prior to C1D1: Absolute neutrophil count ≥1000/mm3, and platelet count ≥100,000/mm3 (patients for whom \<50% of bone marrow nucleated cells are plasma cells). If cytopenias are due a plasma cell infiltration in the bone marrow (biopsy-proven heavy-marrow involvement, as defined by having at least 30% marrow cellularity, with \> 50% of the cells being malignant plasma cells (documented marrow results required)); in this case, although there are no required lower limits of normal for the blood counts, the treating physician must use his/her medical judgment as to the appropriateness of this study therapy for these patients.
   2. Erythropoietin-analogues are allowed.
   3. Patients must have:

      * At least a 1-week interval from the last platelet transfusion prior to the screening platelet assessment.

   However, patients may receive RBC and/or platelet transfusions as clinically indicated per institutional guidelines during the study.
9. Female patients of childbearing potential must have a negative serum pregnancy test at Screening. Female patients of childbearing potential and fertile male patients who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 3 months following the last dose of study treatment.
10. Patients must be able to take prophylactic anticoagulation as recommended by study
11. Patients with pathologic fractures, infection at diagnosis or symptomatic hyperviscosity must have these conditions attended to prior to registration (i.e., intramedullary rod, I.V. antibiotics, plasmapheresis)

Exclusion Criteria:

Exclusion Criteria:

Patients meeting any of the following exclusion criteria are not eligible to enroll in this study:

1. Has received selinexor or another XPO1 inhibitor previously.
2. Has any concurrent medical condition or disease (eg, uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, etc.) that is likely to interfere with study procedures.
3. Known intolerance, hypersensitivity, or contraindication to glucocorticoids, bortezomib, lenalidomide and selinexor.
4. Pregnant or breastfeeding females.
5. Life expectancy of less than 6 months.
6. Active, unstable cardiovascular function, as indicated by the presence of:

   1. Symptomatic ischemia, or
   2. Uncontrolled clinically significant conduction abnormalities (eg, patients with ventricular tachycardia on anti-arrhythmics are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or
   3. Congestive heart failure of New York Heart Association Class ≥3 or known left ventricular ejection fraction \<40%, or
   4. Myocardial infarction within 6 months prior to C1D1.
7. Any active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment.
8. Inability or unwillingness to take supportive medications such as anti-nausea and anti-anorexia agents as recommended by the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (CPGO) (NCCN CPGO) for antiemesis and anorexia/cachexia (palliative care).
9. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.
10. Contraindication to any of the required concomitant drugs or supportive treatments.
11. Patients unwilling or unable to comply with the protocol

Primary outcomes:
measure: Increased ORR in arm B (defined as ≥PR) at end of induction, defined according to IMWG response criteria
timeFrame: Estimated at 4-8 weeks after end of induction
Secondary outcomes:
measure: Increased VGPR rate at end of induction in arm B
timeFrame: Estimated at 4-8 weeks after end of induction
measure: Increased rate of MRD negativity at end of induction in arm B
timeFrame: Estimated at 4-8 weeks after end of induction
measure: Decreased time to response in arm B
timeFrame: Estimated monthly during the first 64 weeks
measure: Evaluate toxicity rates between arm A and B, including rates of secondary primary malignancies
timeFrame: Estimated at 4-8 weeks after end of induction
measure: Decreased time to at least VGPR
timeFrame: Estimated monthly during the first 64 weeks
Other outcomes:
Locations:
city: Aalborg
country: Denmark
facility: Aalborg University Hospital
city: Esbjerg
country: Denmark
facility: Sydvestjysk Sygehus Esbjerg
city: Gødstrup
country: Denmark
facility: Regionshospitalet Gødstrup
city: Odense
country: Denmark
facility: Odense University Hospital
city: Tallinn
country: Estonia
facility: North Estonia Medical Centre Foundation
city: Bergen
country: Norway
facility: Haukeland University Hospital
city: Førde
country: Norway
facility: Førde Central Hospital
city: Kristiansund
country: Norway
facility: Kristiansund Hospital
city: Oslo
country: Norway
facility: Oslo Universitets Hospital
city: Stavanger
country: Norway
facility: Stavanger University Hospital
city: Trondheim
country: Norway
facility: St. Olavs University Hospital
Study officials:
affiliation: Odense University Hospital
name: Ida B Kristensen, MB
role: PRINCIPAL_INVESTIGATOR
affiliation: Oslo University Hospital
name: Hanne Norseth, MD
role: PRINCIPAL_INVESTIGATOR
References: